MRC1 and non-Hodgkin lymphoma: Even though MMR deficient cells have been shown to have a certain degree of tolerance to thiopurines in vitro, clinical data obtained in a large series of CMMRD-associated NHL do not demonstrate an increased risk of treatment failure in CMMRD patients treated with the current standard regimens as compared to patients with sporadic NHL [57].